Crinetics Pharmaceuticals, Inc. 8-K

What Happened
Crinetics Pharmaceuticals, Inc. (CRNX) filed an 8-K reporting that its board approved a title and responsibility change for Jeff Knight, moving him from Chief Operating Officer to Chief Development and Operating Officer. The board approved the change on January 20, 2026, with the new title effective January 2, 2026.

Key Details

• Board approval date: January 20, 2026; effective date of title change: January 2, 2026.
• Executive affected: Jeff Knight — new title: Chief Development and Operating Officer (from Chief Operating Officer).
• No changes to Mr. Knight’s compensation arrangements as described in the Company’s Schedule 14A proxy statement filed April 23, 2025.
• Company disclosed no arrangements or understandings related to his selection, no family relationships with other directors/executive officers, and no reportable related-party transactions involving Mr. Knight.
• The 2025 Proxy Statement contains a description of Mr. Knight’s business experience (incorporated by reference).

Why It Matters
This filing signals an internal reallocation of responsibilities at Crinetics but does not affect executive pay or disclose any related-party concerns. For investors, the change clarifies leadership focus—pairing development oversight with operations—without introducing compensation or governance issues that would require further disclosure.